SCHEMBL3353646

SCHEMBL3353646

Cc1cc(C(=O)O)cc(O)c1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.70
CA1 P00915 4/20 0.70
CA2 P00918 4/20 0.70
CA7 P43166 4/20 0.70
CA9 Q16790 4/20 0.70
CA14 Q9ULX7 4/20 0.70
CA4 P22748 3/20 0.70
CA6 P23280 3/20 0.70
KDM4E B2RXH2 3/20 0.70
CA3 P07451 2/20 0.70
CA5A P35218 2/20 0.70
CA5B Q9Y2D0 2/20 0.70
MAPT P10636 2/20 0.70
LMNA P02545 2/20 0.70
FUT7 Q11130 2/20 0.70
TDP1 Q9NUW8 2/20 0.70
ALDH1A1 P00352 1/20 0.70
TP53 P04637 1/20 0.70
SELL P14151 1/20 0.70
HPGD P15428 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL348297 0.88 CA1 (0.56) CA12CA1CA2CA7CA9
SCHEMBL27690857 0.86 CA1 (0.54) CA12CA1CA2CA7CA9
SCHEMBL28766413 0.86 CA1 (0.54) CA12CA1CA2CA7CA9
SCHEMBL27998994 0.84 CA1 (0.52) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL27648549 0.83 CA12 (0.90) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL2726519 0.83 CA12 (0.90) CA12CA1CA2CA7CA9
SCHEMBL13895617 0.83 POLB (0.57) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL4918056 0.83 CA12 (1.00) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL1845406 0.83 CA12 (1.00) CA12CA1CA2CA7CA9
Gallic Acid SCHEMBL678990 0.83 CA12 (1.00) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016735-A1 IONIC LIQUIDS FOR DRUG DELIVERY PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-01-18 US disclosed
WO-2023196370-A1 LIPID NANOPARTICLES AND LIPOSOMES YEH, TENG-KUANG (US) 2023-10-12 WO disclosed
US-11744820-B2 Inhibitors of microbially induced amyloid AXIAL THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11717549-B2 Steviol glycoside solubility enhancers CARGILL, INCORPORATED (US) 2023-08-08 US disclosed
US-9833425-B2 Gentisic acid is used to improve systemic hemodynamics, hepatic mitochondrial function and lactate acidemia in patients with septic shock UNIVERSITY OF MANITOBA (CA) 2017-12-05 US disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20150336981-A1 MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS CELLAROUGE PTY LTD (AU) 2015-11-26 US disclosed
US-9079989-B2 Charge control resin and manufacturing method of the same ORIENT CHEMICAL INDUSTRIES CO., LTD. (JP) 2015-07-14 US disclosed
US-20150119348-A1 CDK5 Inhibitors and Therapeutic Uses Thereof THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2015-04-30 US disclosed
WO-2012144754-A2 COMPOSITION CONTAINING A GALLA RHOIS EXTRACT HAVING VIRUS INHIBITORY EFFECTS OR A COMPOUND ISOLATED THEREFROM AS AN ACTIVE INGREDIENT, AND USES THEREOF 원광대학교 산학협력단 (KR) 2012-10-26 WO disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed
US-20120037178-A1 MORDANT AND HAIR COLORING PRODUCTS CONTAINING THE SAME NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2012-02-16 US disclosed
WO-2010082845-A1 HONEY ANALYSIS COMVITA NEW ZEALAND LIMITED (NZ) 2010-07-22 WO disclosed
US-7696195-B2 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-04-13 US disclosed
US-20100034762-A1 Novel enrichment methods for gallic acid esters including 1-O-galloy1-bata-D-glucose and mucic acid gallates medicaments, therapeutic applications and methods of treatment thereof MAJEED MUHAMMED 2010-02-11 US disclosed
US-7595074-B2 Polymeric antioxidants UNIVERSITY OF MASSACHUSETTS LOWELL (US) 2009-09-29 US disclosed
EP-1740577-A2 SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-01-10 EP disclosed
US-20050256099-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-17 US disclosed
WO-2005103037-A2 SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG CA12 4325/4885CA1 1797/4885CA2 4265/4885
US-20240016735-A1 IONIC LIQUIDS FOR DRUG DELIVERY SLCO4C1, SLC47A1, ABCB11 CA12 1909/4885CA1 3656/4885CA2 2319/4885
US-20100034762-A1 Novel enrichment methods for gallic acid esters including 1-O-galloy1-bata-D-glucose and mucic acid gallates medicaments, therapeutic applications and methods of treatment thereof GALE, LGALS1, SLC5A1 CA12 992/4885CA1 1415/4885CA2 1792/4885
US-11744820-B2 Inhibitors of microbially induced amyloid APP, PSEN1, BACE1 CA12 3163/4885CA1 448/4885CA2 1223/4885
US-20120037178-A1 MORDANT AND HAIR COLORING PRODUCTS CONTAINING THE SAME TST, TYR, CAT CA12 1261/4885CA1 1450/4885CA2 1193/4885
US-20150336981-A1 MODIFIED POLYPHENOLS AND MODIFIED POLYPHENOL COMPOSITIONS PGC, COMT, EGLN2 CA12 4275/4885CA1 4510/4885CA2 3925/4885
US-11717549-B2 Steviol glycoside solubility enhancers SI, TAS2R7, TAS2R31 CA12 1617/4885CA1 4077/4885CA2 2372/4885
US-20050256099-A1 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA CA12 3064/4885CA1 1869/4885CA2 814/4885
US-20150119348-A1 CDK5 Inhibitors and Therapeutic Uses Thereof CDK5, CDK3, CDKL1 CA12 4595/4885CA1 3587/4885CA2 3583/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG CA12 4325/4885CA1 1797/4885CA2 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.